EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis

Masataka Kuwana, Shoichi Yoshioka, Maki Wakabayashi, Masaya Marumo, Masanari Furuya, Mari Yato, So Saotome, Kazunori Abe

International Journal of Hematology · 30.07.2026

DOI: 10.1007/s12185-026-04259-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, online erschienen am 30.07.2026. Verfasst von Masataka Kuwana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. kuwanam…. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kissei Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fostamatinib was approved in Japan in December 2022 for primary immune thrombocytopenia (ITP). Given the limited clinical trial data, post-marketing surveillance (PMS) was conducted in Japan to collect safety and effectiveness data for fostamatinib. This interim analysis of PMS collected data between April 2023 and April 2025. Most of the 489 patients in the safety analysis set had received ≥ 3 treatment lines. Approximately 70% used fostamatinib with glucocorticoids and/or a thrombopoietin receptor agonist. Adverse drug reactions (ADRs) were reported in 49.5% (serious ADRs in 8.6%). The most common ADRs were diarrhoea (20.0%), hypertension (15.7%), hepatic function abnormal (9.6%), liver disorders (4.9%), and neutrophil count decreased (4.1%). Safety analysis revealed no major differences in the frequency of ADRs, including those of special interest, by combination treatment(s). Median platelet count increased at 2 weeks of treatment and remained above 50,000/μL thereafter, regardless of the ITP treatment combination. Further, complete response (platelet count ≥ 100,000/μL) was observed in 135 of 309 patients at 3 months and 128 of 241 patients at 6 months under continuous fostamatinib use. The results of this real-world PMS revealed no new safety concerns and support the effectiveness of fostamatinib in patients with primary ITP.

Schlagwörter

Stichwörter der Autor:innen

FostamatinibImmune thrombocytopeniaJapanPost-marketing surveillance

Autor:innen und Institutionen

  • Department of Allergy and Rheumatology, Graduate School of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. kuwanam@nms.ac.jp.
  • Pharmacovigilance and Post-Marketing Surveillance Department, Kissei Pharmaceutical Co., Ltd., Tokyo, Japan.

Förderung

  • Kissei Pharmaceutical Co., Ltd.

Zitieren

APA

Kuwana, M., Yoshioka, S., Wakabayashi, M., Marumo, M., Furuya, M., Yato, M., Saotome, S., & Abe, K. (2026). Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis. International Journal of Hematology. https://doi.org/10.1007/s12185-026-04259-2

Vancouver

Kuwana M, Yoshioka S, Wakabayashi M, Marumo M, Furuya M, Yato M, et al. Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis. International Journal of Hematology. 2026. doi:10.1007/s12185-026-04259-2

BibTeX
@article{Kuwana2026,
  author = {Kuwana, Masataka and Yoshioka, Shoichi and Wakabayashi, Maki and Marumo, Masaya and Furuya, Masanari and Yato, Mari and Saotome, So and Abe, Kazunori},
  title = {Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis},
  journal = {International Journal of Hematology},
  year = {2026},
  doi = {10.1007/s12185-026-04259-2}
}
Kostenlos starten →